NEWTOWN, Pa.--(BUSINESS WIRE)--BioClinica®, Inc. (NASDAQ: BIOC), a global provider of clinical trial management solutions, today announced that members of its team will attend, participate in and lead discussions at several upcoming industry conferences in July, August, and September. BioClinica experts will share industry trends and also demonstrate the company’s suite of technologies and solutions. The conferences include:
Osteoarthritis Research Society International (ORSI) 6th
International Workshop on Osteoarthritis Imaging Combined with the OARSI
OA Biomarkers Workshop III – Imaging Biomarker Validation and
Quantification
July 12 – 14, 2012
Hilton Head,
South Carolina
The Osteoarthritis (“OA”) Initiative produces clinical and imaging data that helps identify risk factors for the onset and progression of OA as well as clinically validating imaging biomarkers for clinical trials. This workshop will provide discussion to utilize these resources in an efficient, collaborative, productive, and targeted manner. BioClinica is a workshop sponsor will participate in a variety of programs during the conference. BioClinica’s Senior Vice President of Medical Affairs, Colin G. Miller, Ph.D., F.I.C.R., CSci, will co-present a variety of events including the following:
- Pre-Course Workshop on the Practical Use of Imaging Biomarkers in Clinical Studies/Trials.
- Presentation titled “A 2-Year Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Of Oral Selective Inos Inhibitor, Cindunistat, In Patients With Symptomatic Osteoarthritis Of The Knee”
- Presentation titled “Considerations When Designing A Dmoad Clinical Trial Using Radiography”
- Poster presentation titled “X-Ray Acquistion Challenges In Clinical Trials: Challenges And Solutions Posed By The Synaflexer™”
Alzheimer’s Association International Conference
July 14
– 19, 2012
Vancouver, British Columbia
Booth #
324
At AAIC® 2012 the world's leading dementia scientists will meet to share the latest thoughts and theories in the field. Chahin Pachai, Ph.D, BioClinica’s Vice President and Executive Director, of BioClinica's Lyon, France office, and Medical Affairs Scientist Hui Jing Yu, Ph.D will exhibit at the conference and co-present seven research posters on a variety of topics including the following:
- Multi-Atlas Segmentation of the Hippocampus Refined with Intensity-Based Tissue Classification.
- Accurate Intracranial Cavity Volume Estimation in Mild Cognitively Impaired Population Using Multi- Atlas Segmentation
- Discordance for Hippocampal Atrophy and Amyloid Burden in Amnestic Mild Cognitive Impairment May Identify Distinct Subgroups of Patients
- Choice of Threshold Hippocampal Volume as a Selection Criterion in Prodromal Alzheimer’s Disease
- Impact of Hippocampal Volume–Based Enrichment on Clinical Outcomes in Prodromal AD Trials up to 3-Years Follow-Up
American Society for Bone and Mineral Research
Topical
Meeting on Bone and Skeletal Muscle Interactions
July 17 –
18, 2012
Kansas City, Missouri
ASBMR is a professional, scientific and medical society established to bring together clinical and experimental scientists involved in the study of bone and mineral metabolism. This meeting will draw together leading muscle and bone researchers to exchange ideas, develop new collaborations and accelerate the emerging scientific discoveries in the area of muscle and bone interactions. Dr. Neil Binkley of the University of Wisconsin Osteoporosis Clinical Center and Research Program will present an abstract co-authored with BioClinica’s Senior Vice President of Medical Affairs, Colin G. Miller, Ph.D., F.I.C.R., CSci, titled “Dual energy x-ray absorptiometry body composition: a new phantom for clinical trials.” Dr. Miller will present this abstract at the ASBMR Annual Meeting in October, 2012.
International Bone Densitometry Workshop
August 20 – 24,
2012
Breckenridge, Colorado
BioClinica is proud to sponsor the International Bone Densitometry Workshop. The IBDW educational mission is to update the metabolic bone field in the cutting-edge advances in the radiological assessments of skeletal micro architecture and bone quality. The topics of discussion and presentation by true experts in this field will include advancements in micro-MRI, high resolution central and peripheral QcT, finite element analysis, measurements of cortical porosity, and other newer imaging modalities in bone. BioClinica’s Senior Vice President of Medical Affairs, Colin G. Miller, Ph.D., F.I.C.R., CSci, will attend the workshop.
Clinical Business Expo
September 18 – 20, 2012
Boston,
Massachusetts
Booth # 116
The Clinical Business Expo is where clinical development teams meet with over 700 clinical trial operations executives to collaborate and learn how to improve clinical trial operations. The expo will feature five distinct events to choose from and six shared keynote sessions on non-traditional partnerships, negotiation strategies, change management, patient centricity, and turning data into knowledge. BioClinica representatives will demonstrate the company’s industry-leading eClinical solutions and Imaging Core Lab services.
Society for Clinical Data Management 2012 Annual Conference
September
22 – 23, 2012
Los Angeles, California
Booth # 123
Since its founding in 1994, SCDM has promoted quality and excellence in data management. The SCDM Annual Conference is the world's largest education event for clinical data managers and related professionals, attracting over 600 attendees from across North America and around the world. Jonathan Andrus, BioClinica’s Senior Vice President of Operations for its eClinical Division, will chair a session focused on collaboration between data management and clinical monitoring professionals to improve data quality and increase the speed and quality of study management. BioClinica is a sponsor of this event and will have representatives on hand to demonstrate the company’s industry-leading eClinical solutions.
Outsourcing in Clinical Trials New England
September 25 –
26
Boston, Massachusetts
Booth #46
Among the most crucial aspects of running a successful clinical trial is the procurement of an efficient and trustworthy outsourcing partner. The 4th annual Outsourcing in Clinical Trials New England conference will showcase real innovation and cutting-edge presentations covering all areas of clinical outsourcing. Outsourcing in Clinical Trials New England will help pharmaceutical, biotech, and medical device companies of all levels define and refine their operational efficiency to ensure smooth running of trial procedures, from start-up to database closure. BioClinica representatives will attend the conference to demonstrate the company’s industry-leading eClinical solutions and Imaging Core Lab services.
About BioClinica, Inc.
BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management solutions. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management and clinical supply chain design and optimization solutions. BioClinica solutions maximize efficiency and manageability throughout all phases of the clinical trial process. With over 20 years of experience and more than 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com.
Certain matters discussed in this press release are “forward-looking statements” intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company’s financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company’s filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.